126 related articles for article (PubMed ID: 29472310)
1. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
Reyes-Botero G; Cartalat-Carel S; Chinot OL; Barrie M; Taillandier L; Beauchesne P; Catry-Thomas I; Barrière J; Guillamo JS; Fabbro M; Frappaz D; Benouaich-Amiel A; Le Rhun E; Campello C; Tennevet I; Ghiringhelli F; Tanguy ML; Mokhtari K; Honnorat J; Delattre JY
Oncologist; 2018 May; 23(5):524-e44. PubMed ID: 29472310
[TBL] [Abstract][Full Text] [Related]
2. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
Tanaka T; Tamura R; Takei J; Morimoto Y; Teshigawara A; Yamamoto Y; Imai R; Kuranari Y; Tohmoto K; Hasegawa Y; Akasaki Y; Murayama Y; Miyake K; Sasaki H
J Neurooncol; 2024 Feb; 166(3):557-567. PubMed ID: 38291182
[TBL] [Abstract][Full Text] [Related]
3. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien CI; Pugh SL; Dicker AP; Raizer JJ; Matuszak MM; Lallana EC; Huang J; Algan O; Deb N; Portelance L; Villano JL; Hamm JT; Oh KS; Ali AN; Kim MM; Lindhorst SM; Mehta MP
J Clin Oncol; 2023 Feb; 41(6):1285-1295. PubMed ID: 36260832
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study.
Liao Y; Bai X; Cao Y; Zhang M
J Clin Neurosci; 2024 Feb; 120():196-203. PubMed ID: 38277995
[TBL] [Abstract][Full Text] [Related]
5. Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score-matching analysis.
Liu YL; Liu PF; Shao W; Du HP; Li ZZ; Guo C; Li ZF
Onco Targets Ther; 2017; 10():4029-4035. PubMed ID: 28860811
[TBL] [Abstract][Full Text] [Related]
6. Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.
Xue W; Du X; Wu H; Liu H; Xie T; Tong H; Chen X; Guo Y; Zhang W
Sci Rep; 2017 Oct; 7(1):13894. PubMed ID: 29066764
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and Treatment Algorithm in Glioblastoma Patients 80 Years and Older.
Fogg D; Gersey ZC; Pease M; Mallela AN; Andrews E; Plute T; Pearce TM; Njoku-Austin C; Anthony A; Amankulor NM; Zinn P
World Neurosurg; 2023 Oct; 178():e540-e548. PubMed ID: 37516146
[TBL] [Abstract][Full Text] [Related]
8. The addition of Valproic acid to concurrent radiation therapy and temozolomide improves patient outcome: a Correlative analysis of RTOG 0525, SEER and a Phase II NCI trial.
Krauze AV; Megan M; Theresa CZ; Peter M; Shih JH; Tofilon PJ; Rowe L; Gilbert M; Camphausen K
Cancer Stud Ther; 2020 Mar; 5(1):. PubMed ID: 34621499
[TBL] [Abstract][Full Text] [Related]
9. Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States.
Davies J; Reyes-Rivera I; Pattipaka T; Skirboll S; Ugiliweneza B; Woo S; Boakye M; Abrey L; Garcia J; Burton E
Neurooncol Pract; 2018 Nov; 5(4):251-261. PubMed ID: 31385957
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Stadler C; Gramatzki D; Le Rhun E; Hottinger AF; Hundsberger T; Roelcke U; Läubli H; Hofer S; Seystahl K; Wirsching HG; Weller M; Roth P
Neurooncol Pract; 2024 Apr; 11(2):132-141. PubMed ID: 38496908
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study.
Lulla RR; Buxton A; Krailo MD; Lazow MA; Boue DR; Leach JL; Lin T; Geller JI; Kumar SS; Nikiforova MN; Chandran U; Jogal SS; Nelson MD; Onar-Thomas A; Haas-Kogan DA; Cohen KJ; Kieran MW; Gajjar A; Drissi R; Pollack IF; Fouladi M
Neurooncol Adv; 2024; 6(1):vdae035. PubMed ID: 38596718
[TBL] [Abstract][Full Text] [Related]
12. NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Sim HW; Wachsmuth L; Barnes EH; Yip S; Koh ES; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; McDonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M
Neurooncol Adv; 2023; 5(1):vdad124. PubMed ID: 37841696
[TBL] [Abstract][Full Text] [Related]
13. The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report.
Harari-Turquie M; Moturi KR; Horton DD; Rabinowitz I
J Investig Med High Impact Case Rep; 2023; 11():23247096231193266. PubMed ID: 37596951
[TBL] [Abstract][Full Text] [Related]
14. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence.
Christ SM; Youssef G; Tanguturi SK; Cagney D; Shi D; McFaline-Figueroa JR; Chukwueke U; Lee EQ; Hertler C; Andratschke N; Weller M; Reardon DA; Haas-Kogan D; Guckenberger M; Wen PY; Rahman R
Clin Transl Radiat Oncol; 2024 Jan; 44():100697. PubMed ID: 38046107
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy of Bevacizumab Combined with Temozolomide in Treating Gliomas.
Li P; Qi A; Li Q
Altern Ther Health Med; 2024 May; ():. PubMed ID: 38758157
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Vize CJ; Kim SK; Matthews T; Macsai M; Merrell R; Hsu S; Kundu MG; Yoon J; Kennedy E; Pai M; Bain E; Lassman AB; Moazami G
Ophthalmic Res; 2023; 66(1):1030-1043. PubMed ID: 37257422
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
Goldlust SA; Nabors LB; Hsu S; Mohile N; Duic PJ; Benkers T; Singer S; Rao M; Cappello L; Silberman SL; Farmer G
Neurooncol Adv; 2024; 6(1):vdae009. PubMed ID: 38327681
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials.
Xie X; Bao S; Zhao H; Li L; Fu X
Cancer Invest; 2023 Feb; ():1-13. PubMed ID: 36705341
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Nanomedicine in Glioblastoma Treatment: Clinical Efficacy, Safety, and Future Directions.
Farooq M; Scalia G; Umana GE; Parekh UA; Naeem F; Abid SF; Khan MH; Zahra SG; Sarkar HP; Chaurasia B
Brain Sci; 2023 Dec; 13(12):. PubMed ID: 38137175
[TBL] [Abstract][Full Text] [Related]
20. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
